Pilot Study DiaDEP

Diabetes Mellitus, Type 1 Clinical Trial

— DiaDEP  

Official title:

Endothelial Dysfunction Could be an Early Biomarker of Renal Impairment in Children and Adolescent With Type 1 Diabetes. Pilot Study DiaDEP

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03912012
• Other study ID #: 69HCL17_0518
• Status: Completed
• Phase: N/A
• Start date: July 9, 2019
• Est. completion date: November 20, 2020

Study information

• Verified date: February 2024
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

With an increased incidence of pediatric type 1 diabetes (T1D) and a decrease in age at diagnosis, children are exposed to complications such as renal impairment at a very young age.

The current biomarker used to diagnose renal impairment is microalbuminuria, but it's a late marker. Early screening is a major issue to reduce T1D consequences.

Early glomerular hyperfiltration (GHF) could participate in the development and progression of nephropathy. Hyperfiltration has also been associated with a systemic endothelial dysfunction and with changes in arterial stiffness, suggesting, at least to a certain extent, a state of generalized vascular dysfunction.

Diabetes is responsible for very early neurovascular dysfunctions, detectable with techniques to evaluate cutaneous neurovascular interaction. Those should help bringing to light very early microcirculation impairment, particularly precocious endothelial dysfunction (ED).

No study about correlation between GHF and ED is currently available. The hypothesis assessed is those of a strong correlation between ED and GHF in children and adolescent with a story of T1D for at least 10 years.

This pilot study should allow assessing ED's and GHF's proportions in our population, in order to conduct a larger study to prove, in a prospective way, the prognostic value of ED in the apparition of nephropathy, taking into count other factors such as diabetes duration or stability.

This measure could be included in the global evaluation of microangiopathy risk in children and then take action to prevent negative outcomes.

The second aspect of this study is the assessment of other functions and metabolisms possibly impaired in T1D: osseous microarchitecture, vitamin D status and precocious evaluation of macro angiopathy through intima media thickness measurement.

Long term diabetes in children is associated with shorter and leaner bones, despite a correct mineralization, a reduced bone density and a fracture risk increased six fold. Bone status in the population will be evaluated through the study of bones microarchitecture via HR-pQCT (High Resolution peripheral Quantitative Computed Tomography) on both tibia and radius, dual-energy X-ray absorptiometry (DXA), and bone turn over biochemical markers.

Results on bone microarchitecture in a preexisting cohort of healthy children and adolescents will be used to compare results.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: November 20, 2020
• Est. primary completion date: November 20, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 10 Years to 18 Years

Eligibility

Inclusion Criteria:

• Aged = 10 et < 18 years old

• Type 1 diabetes diagnosed more than 10 years previously.

• Written informed consent signed by both parents or legal representatives, child or adolescent's agreement.

• Health cover

Exclusion Criteria:

• Associated pathology with a potential impact on cutaneous microcirculation or renal function.

• Aspirin or other non-steroid anti-inflammatory treatment with potential impact on endothelial function in the 3 weeks preceding the visit.

• Examination with injection of contrast agent during the last 48 hours

• Smoking

• Ongoing pregnancy or breast feeding

• Hypersensitivity to acetylcholine

• Contraindication to Iohexol

• Ongoing treatment with growth hormone, non-inhaled corticosteroids or anti-calcineurins;

• History of treatment with oral corticosteroids (not inhaled) more than 3 successive months regardless of seniority;

• Paracetamol treatment less than a week old;

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 1
• Type1diabetes

Intervention

Drug:
• Iohexol renal clearance measurement
intravenous injection of Iohexol (Omnipaque 300mg) with blood sampling at 0, 120, 180 and 240 minutes (during Day 1.

Device:
• microcirculation assessment through Laser Doppler associated to iontophoresis.
endothelial function evaluated following a protocol of iontophoresis of acetylcholine (during Day 1).
• Cardiovascular assessment though Intima-media Thickness and Extra-media Thickness measurement
carotid ultrasound (during Day 1)

Biological:
• Blood sampling
37 mL of blood sample will be performed at Day 1
• Urine sampling
The urinary collection will be done during the Day 1, on the first morning urination

Device:
• High-resolution peripheral quantitative computed tomography (HR-pQCT)
assessment of the Body Mass Index by HR-pQCT (during the Day 1)

Radiation:
• Dual-energy X-ray (DXA)
assessment of bone parameters by DXA (during the Day 1)

Locations

Country	Name	City	State
France	Hopital Femme Mère Enfant - Groupement Hospitalier Est	Bron

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Glomerular hyper filtration (Glomerular filtration > 135 mL/min/1,73 m2)	assessed through Iohexol renal clearance measurement	Day 1
Secondary	Endothelial function in the forearm.	Endothelial function will be evaluated by the microcirculation assessment through Laser Doppler associated to iontophoresis of acetylcholine.	Day 1
Secondary	Intima media thickness	The intima media thickness will be performed by Echo Doppler of both right and left common carotid	Day 1
Secondary	arterial blood pressure	arterial blood pressure measurement	Day 1
Secondary	Bone mass	Bone mass will be performed by Dual-energy X-ray absorptiometry (DXA) on both spine and whole body.	Day 1
Secondary	bone density	bone density will be performed by Dual-energy X-ray absorptiometry (DXA) on both spine and whole body.	Day 1
Secondary	quantization of bone mineral content	quantization of bone mineral content will be performed by Dual-energy X-ray absorptiometry (DXA) on both spine and whole body.	Day 1
Secondary	Volumetric compartmental density	Volumetric compartmental density will be performed by High Resolution peripheral Quantitative Computed Tomography (HR-pQCT) on radius and tibia (Right tibia and non-dominant arm radius). (Unless there is a history of fracture for one of those bones, in which case the opposite side will be studied instead.)	Day 1
Secondary	trabecular microarchitecture	trabecular microarchitecture will be performed by High Resolution peripheral Quantitative Computed Tomography (HR-pQCT) on radius and tibia (Right tibia and non-dominant arm radius). (Unless there is a history of fracture for one of those bones, in which case the opposite side will be studied instead.)	Day 1